Eli Lilly - 52 Year Stock Price History | LLY

Historical daily share price chart and data for Eli Lilly since 1972 adjusted for splits and dividends. The latest closing stock price for Eli Lilly as of April 16, 2024 is 746.74.
  • The all-time high Eli Lilly stock closing price was 792.28 on March 04, 2024.
  • The Eli Lilly 52-week high stock price is 800.78, which is 7.2% above the current share price.
  • The Eli Lilly 52-week low stock price is 369.75, which is 50.5% below the current share price.
  • The average Eli Lilly stock price for the last 52 weeks is 575.94.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Eli Lilly Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 719.6737 591.1852 792.2800 591.1852 746.7400 28.32%
2023 462.1139 360.8148 616.9277 308.0750 581.9211 60.91%
2022 302.2881 265.0338 370.4730 229.8624 361.6550 34.24%
2021 217.7263 159.0140 272.1637 157.8803 269.4131 66.08%
2020 141.6073 124.5126 165.8646 112.7039 162.2231 31.06%
2019 108.9539 106.4092 124.7198 99.9935 123.7780 15.48%
2018 85.8450 76.5173 109.8919 67.0565 107.1872 40.45%
2017 73.3779 65.6922 79.4179 65.6746 76.3185 17.83%
2016 66.4243 71.0723 72.6690 58.0927 64.7676 -10.37%
2015 66.7968 58.5352 76.6911 57.5652 72.2644 25.37%
2014 50.7732 41.0266 60.8496 41.0266 57.6412 39.75%
2013 41.8380 38.6094 45.9045 38.1657 41.2449 7.24%
2012 33.2821 31.1295 41.5309 29.0260 38.4612 24.27%
2011 26.7584 24.7032 31.0922 24.0731 30.9507 25.15%
2010 24.1669 23.9195 26.4919 22.1522 24.7314 3.71%
2009 22.3143 25.6244 25.6244 17.5819 23.8461 -6.25%
2008 28.0789 31.7820 34.5822 18.8915 25.4350 -21.23%
2007 33.0616 30.6505 35.8034 29.6894 32.2900 5.65%
2006 31.8515 32.6635 33.9192 29.1396 30.5625 -5.16%
2005 30.9031 31.1565 33.8796 28.1278 32.2250 2.52%
2004 36.0685 38.6176 41.5353 27.7612 31.4334 -17.55%
2003 34.0887 35.1494 40.0541 28.6573 38.1243 13.14%
2002 34.0716 40.8505 42.1612 25.2795 33.6955 -17.56%
2001 41.2155 46.9682 46.9682 37.3919 40.8714 -14.44%
2000 40.1549 33.1829 55.3400 27.7013 47.7690 41.92%
1999 38.0521 42.9926 48.8398 31.0340 33.6587 -24.25%
1998 35.5081 34.0810 45.4322 28.8834 44.4323 29.08%
1997 25.8025 17.6079 34.5754 17.6079 34.4221 94.15%
1996 15.1666 13.1601 19.2473 11.7628 17.7294 32.64%
1995 9.4015 7.4929 13.4263 7.2208 13.3669 77.39%
1994 6.3447 6.5184 7.5354 5.2707 7.5354 15.60%
1993 5.5431 6.4270 6.6546 4.7370 6.5184 2.47%
1992 7.0467 8.6093 8.8365 6.1105 6.3611 -24.89%
1991 7.7751 7.2257 8.6093 6.8533 8.4694 16.41%
1990 7.0387 6.6410 8.8148 5.7722 7.2754 9.95%
1989 5.4364 4.0362 6.6169 4.0362 6.6169 64.17%
1988 3.8587 3.6531 4.2907 3.2523 4.0306 12.81%
1987 4.0067 3.3787 4.7607 2.8213 3.5729 5.75%
1986 3.1764 2.4971 3.7542 2.3151 3.3787 33.18%
1985 1.9298 1.4762 2.5369 1.4732 2.5369 68.94%
1984 1.3854 1.3538 1.5217 1.2286 1.5017 14.03%
1983 1.4255 1.3055 1.5558 1.2912 1.3169 0.66%
1982 1.2947 1.2684 1.4789 1.0580 1.3083 2.68%
1981 1.3271 1.4334 1.5529 1.0607 1.2741 -11.98%
1980 1.2125 1.3196 1.4475 1.0493 1.4475 6.71%
1979 1.2584 1.0921 1.4448 1.0835 1.3565 24.86%
1978 1.0238 0.8589 1.2229 0.8362 1.0864 26.05%
1977 0.8829 1.0721 1.0721 0.7481 0.8619 -20.45%
1976 1.1735 1.1631 1.3651 0.9925 1.0835 -7.75%
1975 1.4961 1.5271 1.8002 1.1576 1.1745 -24.09%
1974 1.5779 1.6696 1.8684 1.2798 1.5472 -8.11%
1973 1.8568 1.8002 2.0846 1.5954 1.6837 -7.06%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $709.526B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $553.986B 45.64
Johnson & Johnson (JNJ) United States $348.093B 13.81
Merck (MRK) United States $316.781B 83.37
AbbVie (ABBV) United States $287.801B 14.63
AstraZeneca (AZN) United Kingdom $211.650B 18.75
Novartis AG (NVS) Switzerland $197.547B 13.69
Pfizer (PFE) United States $145.471B 14.04
Sanofi (SNY) $115.856B 10.43
Innoviva (INVA) United States $0.915B 6.46